MA40580A - Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques - Google Patents

Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Info

Publication number
MA40580A
MA40580A MA040580A MA40580A MA40580A MA 40580 A MA40580 A MA 40580A MA 040580 A MA040580 A MA 040580A MA 40580 A MA40580 A MA 40580A MA 40580 A MA40580 A MA 40580A
Authority
MA
Morocco
Prior art keywords
integrin
antagonists
beta
alpha
treatment
Prior art date
Application number
MA040580A
Other languages
English (en)
Other versions
MA40580B1 (fr
Inventor
Niall Andrew Anderson
Matthew Howard James Campbell-Crawford
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40580A publication Critical patent/MA40580A/fr
Publication of MA40580B1 publication Critical patent/MA40580B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Abstract

L'invention concerne un composé de formule (i), ce dernier étant un acide 4-(3-fluoro-3-(2-(5, 6, 7, 8-tétrahydro-l, 8-naphthyridin-2-yl) éthyl) pyrrolidin-l-yl)-3-(3-(2-méthoxyéthoxy) phényl) butanoïque, ou un sel de ce dernier.
MA40580A 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques MA40580B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
EP15767475.5A EP3197892B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
PCT/EP2015/071776 WO2016046225A1 (fr) 2014-09-26 2015-09-22 Nouveaux composés

Publications (2)

Publication Number Publication Date
MA40580A true MA40580A (fr) 2017-08-02
MA40580B1 MA40580B1 (fr) 2018-09-28

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40580A MA40580B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Country Status (36)

Country Link
US (3) US9956209B2 (fr)
EP (2) EP3428167A1 (fr)
JP (1) JP6611799B2 (fr)
KR (1) KR101998000B1 (fr)
CN (1) CN107074848B (fr)
AR (1) AR101994A1 (fr)
AU (1) AU2015320858B2 (fr)
BR (1) BR112017006251A2 (fr)
CA (1) CA2962315A1 (fr)
CL (1) CL2017000705A1 (fr)
CO (1) CO2017002714A2 (fr)
CR (1) CR20170112A (fr)
CY (1) CY1121071T1 (fr)
DK (1) DK3197892T3 (fr)
DO (1) DOP2017000081A (fr)
EA (1) EA031481B1 (fr)
ES (1) ES2690748T3 (fr)
GB (1) GB201417002D0 (fr)
HR (1) HRP20181796T1 (fr)
HU (1) HUE041827T2 (fr)
IL (1) IL250592A0 (fr)
JO (1) JO3413B1 (fr)
LT (1) LT3197892T (fr)
MA (1) MA40580B1 (fr)
MX (1) MX2017003948A (fr)
PE (1) PE20170502A1 (fr)
PH (1) PH12017500361B1 (fr)
PL (1) PL3197892T3 (fr)
PT (1) PT3197892T (fr)
RS (1) RS58000B1 (fr)
SG (1) SG11201701183YA (fr)
SI (1) SI3197892T1 (fr)
TW (1) TW201629056A (fr)
UA (1) UA119181C2 (fr)
UY (1) UY36314A (fr)
WO (1) WO2016046225A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
CA3042684A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Amides d'azole et amines en tant qu'inhibiteurs d'integrine .alpha.v
EP3538526B1 (fr) 2016-11-08 2024-04-10 Bristol-Myers Squibb Company Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
US10717736B2 (en) * 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors
LT3538525T (lt) 2016-11-08 2022-09-26 Bristol-Myers Squibb Company Propiono rūgštys, pakeistos 3 padėtyje, kaip alfa v integrino inhibitoriai
AU2017359027A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
JP7291696B2 (ja) 2017-11-07 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロロピラジン誘導体
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
EP3843728A4 (fr) * 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
WO2020047208A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
US20210347898A1 (en) * 2018-10-09 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
MX2021006544A (es) * 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
WO2000072801A2 (fr) 1999-06-02 2000-12-07 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
EP1229910A4 (fr) * 1999-10-04 2003-10-01 Merck & Co Inc Antagonistes des recepteurs d'integrine
EP1230240B1 (fr) 1999-11-08 2003-07-23 Merck & Co., Inc. Procede de preparation et intermediaires de preparation d'antagonistes de l'integrine alpha v d'imidazolidinone
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
ES2280383T3 (es) 2000-07-26 2007-09-16 MERCK & CO., INC. Antagonistas de receptores de integrina alfa v.
WO2002022616A2 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
EP1349548A4 (fr) 2001-01-03 2004-06-02 Merck & Co Inc Methodes et compositions de traitement d'une parodontopathie
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
IL164021A0 (en) 2002-03-13 2005-12-18 Univ California Antibodies and anti-pharmaceutical compositions containing the same
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
JP2006518333A (ja) 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
ES2446417T3 (es) 2007-03-23 2014-03-07 Amgen Inc. Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K)
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (fr) 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016219906B2 (en) 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
JP2017528507A (ja) 2017-09-28
EP3197892A1 (fr) 2017-08-02
US9956209B2 (en) 2018-05-01
BR112017006251A2 (pt) 2017-12-12
SG11201701183YA (en) 2017-04-27
HUE041827T2 (hu) 2019-05-28
DK3197892T3 (en) 2018-11-26
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
KR101998000B1 (ko) 2019-07-08
RS58000B1 (sr) 2019-01-31
PL3197892T3 (pl) 2019-05-31
DOP2017000081A (es) 2017-04-30
UA119181C2 (uk) 2019-05-10
PH12017500361A1 (en) 2017-07-17
PE20170502A1 (es) 2017-04-27
US10342783B2 (en) 2019-07-09
CR20170112A (es) 2017-05-26
EA031481B1 (ru) 2019-01-31
UY36314A (es) 2016-04-29
JO3413B1 (ar) 2019-10-20
CN107074848A (zh) 2017-08-18
HRP20181796T1 (hr) 2018-12-28
PH12017500361B1 (en) 2017-07-17
EP3197892B1 (fr) 2018-09-05
CY1121071T1 (el) 2019-12-11
AR101994A1 (es) 2017-01-25
CO2017002714A2 (es) 2017-06-30
US20170290817A1 (en) 2017-10-12
US20180271845A1 (en) 2018-09-27
MA40580B1 (fr) 2018-09-28
US20190275016A1 (en) 2019-09-12
WO2016046225A1 (fr) 2016-03-31
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
MX2017003948A (es) 2017-06-26
CA2962315A1 (fr) 2016-03-31
EP3428167A1 (fr) 2019-01-16
PT3197892T (pt) 2018-12-12
CL2017000705A1 (es) 2017-11-03
AU2015320858B2 (en) 2018-10-18
KR20170055489A (ko) 2017-05-19
AU2015320858A1 (en) 2017-03-09
CN107074848B (zh) 2019-11-01
EA201790715A1 (ru) 2017-07-31
ES2690748T3 (es) 2018-11-22
JP6611799B2 (ja) 2019-11-27
TW201629056A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
MA40580A (fr) Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MA35725B1 (fr) Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk
PH12016501440A1 (en) Novel heterocyclic compounds
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA40302B1 (fr) Dérivés de carbazole
WO2015100092A3 (fr) Analogues 7-bêta d'orvinols
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
NZ737533A (en) 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2c antagonists
WO2017081702A3 (fr) Procédé de préparation d'enzalutamide.
EA201600507A2 (ru) Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
MA41311B1 (fr) Peptides antagonistes du cgrp
PL399182A1 (pl) Sposób wytwarzania nilotinibu
MA38973B1 (fr) Aminohétéroaryles benzamides en tant qu'inhibiteurs de kinase
FR3022245B1 (fr) Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation